AstraZeneca shares fell nearly 3% in premarket trading.Total revenue jumped 47% to $9.74 billion for the three months to September on a constant-currency basis, while core earnings came in at $1.08 per share, the company said.
Analysts on average were expecting profit of $1.28 per share on sales of $9.4 billion, according to Refinitiv IBES data.
精彩评论